Figure 1From: Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies Computerized tomography scans of the metastatic tumors at baseline (A) and after 2 months (B) showing cavity formation.Back to article page